Viz.ai has been recognised in the inaugural Forbes AI list as one of the USA’s 50 most promising artificial intelligence (AI) companies. The company uses AI to synchronize stroke care, with the aim of reducing time to treatment and expanding patient access to life-saving care. The Forbes AI list highlights the most promising private companies that are applying AI to solve problems in innovative ways.
A press release reports that Viz.ai focuses on ensuring the right patient sees the right doctor at the right time. CEO Chris Mansi comments: “Artificial Intelligence can have a real impact on patient care by enabling efficient health systems that deliver better patient outcomes.”
Don Frei (Radiology Imaging Associates PC, Englewood, USA) states: “Viz.ai is the future of how healthcare needs to be implemented. I am made aware of potential strokes within minutes of the patient receiving their scan and can coordinate care even if the patient is a hundred miles away. I am excited to see how this can be applied to even more disease states.”
In February 2018, the FDA granted a de novo clearance for Viz LVO—the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.